Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Methotrexate in the treatment of ankylosing spondylitis
Author: Sampaio-Barros, PD
Costallat, LTL
Bertolo, MB
Neto, JFM
Samara, AM
Abstract: The authors carried out an open prospective study analyzing methotrexate (MTX) efficacy and toxicity in 34 patients with ankylosing spondylitis (AS) for a period of one year. All the patients presented with active axial disease, characterized by inflammatory spinal pain, prolonged morning stiffness, erythrocyte sedimentation rate(ESR) greater than or equal to 25 mm, and failure on treatment with non-steroidal anti-inflammatory drugs for a period of more than two years. MTF; was taken at a single weekly intramuscular dose of 12.5,ng. Thirty-one patients (91%) concluded treatment. Eighteen patients (53%) were considered responders to MTX; most of them presented peripheral arthritis. Despite clinical improvement, axial measures were unaltered at the end of the study. The mean value of ESR decreased significantly at the end of the treatment (p=0.0001), predominantly in the responders group. Side effects were observed in 23 patients (68%) and included dyspeptic syndrome. transient elevation of liver enzymes, and dizziness. The results of this one year open study suggest that MTX can be an efficient drug in the treatment of AS.
Subject: ankylosing spondylitis
slow acting antirheumatic drug
Country: Noruega
Editor: Taylor & Francis As
Citation: Scandinavian Journal Of Rheumatology. Taylor & Francis As, v. 29, n. 3, n. 160, n. 162, 2000.
Rights: fechado
Date Issue: 2000
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000087805500004.pdf53.28 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.